Barclays PLC Biocryst Pharmaceuticals Inc Put Options Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 15, 2024	BUY	$6.41 - $8.69 $64,100 - $86,900	10,000 New	10,000 $76,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $195,600 - $306,000	-40,000 Reduced 66.67%	20,000 $102,000
Q4 2023 Feb 15, 2024	BUY	$4.98 - $6.77 $298,800 - $406,200	60,000 New	60,000 $359,000
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $294,783 - $926,895	101,300 Added 91.92%	211,500 $802,000
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $707,742 - $932,148	95,900 Added 670.63%	110,200 $897,000
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $41,664 - $61,440	-6,400 Reduced 30.92%	14,300 $115,000
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $78,384 - $113,458	14,200 Added 218.46%	20,700 $158,000
Q2 2018 Aug 14, 2018	SELL	$4.6 - $6.52 $3,679 - $5,216	-800 Reduced 10.96%	6,500 $37,000
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $63,509 - $84,972	-14,600 Reduced 66.67%	7,300 $35,000
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $11,648 - $14,924	-2,800 Reduced 11.34%	21,900 $108,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $101,269 - $147,459	24,700	24,700 $129,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.